• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Congresswoman DeLauro proposes pharma price legislation

Congresswoman DeLauro proposes pharma price legislation

October 18, 2016
CenterWatch Staff

Congresswoman Rosa DeLauro (CT-03) has announced the Prescription Drug and Medical Device Review Board Act, new legislation that would create a national review board to stop pharmaceutical corporations from charging consumers excessive prices. According to a recent report released by IMS Health Holdings, annual spending on prescription medications has skyrocketed in the U.S. in recent years, and is projected to increase by 22% over the next five years, climbing to as high as $400 billion by 2020.

“While American families are paying for increases in medication prices, pharmaceutical corporations are collecting record profits. These companies grow their businesses with the benefit of taxpayer-sponsored research, our skilled workforce, our infrastructure, and tax incentives, only to then gouge those same taxpayers—putting life-saving medicine out of reach for many,” said DeLauro. “The need for more oversight was made clear with Mylan’s recent behavior, which put corporate profits ahead of the health and safety of American children and families. It is irresponsible, inexcusable, and dangerous. While not all companies have engaged in these predatory practices, we must hold bad actors accountable.”

There have been several recent cases of pharmaceutical companies charging consumers excessive prices, including when:

  • Mylan raised the price of lifesaving EpiPens from $100 per two-pack in 2008, to more than $600 in 2016, while at the same time, the CEO’s pay soared more than 700 percent to $19 million;
  • Turing Pharmaceuticals purchased Daraprim—a drug used to treat illnesses that are common among AIDS patients—and overnight raised its price from $13.50 per pill to $750 per pill;
  • The Hepatitis C drug Sovaldi—which can cure the disease over a 12 week period of treatment—came onto the market at $1,000 per pill and $84,000 for a full course of treatment in the U.S.; and
  • Valeant Pharmaceuticals raised the price of Targretin—which is used to treat skin conditions associated with cancer from $31.98 in 2010 to $145.65 in 2014. 

DeLauro’s legislation would establish an Interagency Drug and Device Price Review Board to collect data on drug and device prices and manufacturing costs, and if necessary, take enforcement action against manufacturers that charge consumers excessive prices. This bill will ensure that American families retain access to life-saving drugs by allowing the Price Review Board to take enforcement action against pharmaceutical corporations, including shortening monopoly protections, imposing monetary fines, and recouping previous tax benefits for life saving treatments.

DeLauro’s bill has been endorsed by the Center for Medicare Advocacy, the Connecticut State Medical Society, and AIDS CT. DeLauro plans to introduce the legislation as soon as Congress returns to Washington next month.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing